段良偉（1987.02-），博士，以人類健康為己任，聚焦于以下三個(gè)方面的轉(zhuǎn)化和基礎(chǔ)研究：1.新發(fā)再發(fā)傳染病病原入侵宿主細(xì)胞的分子機(jī)制，為創(chuàng)新藥物的研發(fā)提供支撐；2.新發(fā)再發(fā)傳染病病原的新型免疫原設(shè)計(jì)、全人源中和抗體的研究與開發(fā)；3.新發(fā)再發(fā)傳染病病原檢測(cè)試劑盒的研發(fā)。同時(shí)積極推動(dòng)基礎(chǔ)研究成果向臨床轉(zhuǎn)化。
【受教育經(jīng)歷】
2006.09-2010.07 德州學(xué)院 生物技術(shù)專業(yè) 本科
2010.09-2012.07 南開大學(xué) 生化與分子專業(yè) 碩士
2012.09-2016.07 南開大學(xué) 生化與分子專業(yè) 博士
【研究工作經(jīng)歷】
2016.07-至今 新鄉(xiāng)醫(yī)學(xué)院醫(yī)學(xué)檢驗(yàn)學(xué)院 講師
【承擔(dān)及完成國家級(jí)/省級(jí)課題】
1.強(qiáng)效SARS-CoV-2中和抗體的篩選、表征及中和機(jī)制的研究（222102310025），河南省科技攻關(guān)項(xiàng)目，2022.01-2023.12，10萬元；
2. HTLV-1包膜糖蛋白介導(dǎo)病毒和細(xì)胞膜融合的分子機(jī)制（182300410327），河南自然科學(xué)基金面上項(xiàng)目，2018.01-2019.12，10萬元。
【代表性論著】（#為第一作者，*為通訊作者）
1. Zheng, Qianqian#.Duan, Liangwei#*; Jiang, Zhihua#; Gu, Tingxuan#; Zhang, Bojie; Li, Jiaoyang; Zhang, Yang; Zhang, Shiyu; Liang, Yinming; Wang, Hui*, Two human monoclonal SARS-CoV-2 antibodies that maintain neutralizing potency against the SARS-CoV-2 Omicron BA. 1 and BA. 2 variants;Genes & diseases, 2022 ;doi: 10.1016/j.gendis.2022.05.027.
2. Zheng, Qianqian#;Duan, Liangwei#; Lou, Yunwei#; Chao, Tianzhu; Guo, Guo; Lu, Liaoxun; Zhang, Hongxia; Zhao, Yucong; Liang, Yinming*; Wang, Hui*, Slfn4 deficiency improves MAPK-mediated inflammation, oxidative stress, apoptosis and abates atherosclerosis progression in apolipoprotein E-deficient mice;Atherosclerosis, 2021 ;337: 42-52.
3.Duan, Liangwei; Zheng, Qianqian; Zhang, Hongxia; Niu, Yuna; Lou, Yunwei; Wang, Hui*, The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens;Frontiers in Immunology, 2020 ;11: 576622.
4. A non-canonical binding interface in the crystal structure of HIV-1 gp120 core in complex with CD4;Duan, Liang-Wei#; Zhang, Hui#; Zhao, Meng-Ting; Sun, Ji-Xue; Chen, Wen-Li; Lin, Jian-Ping; Liu, Xin-Qi*,Scientific Reports, 2017; 7: 46733.
5.Duan, Liangwei; Du, Jiansen; Wang, Xuefeng; Zhou, Jianhua; Wang, Xiaojun; Liu, Xinqi*, Structural and functional characterization of EIAV gp45 fusion peptide proximal region and asparagine-rich layer;Virology, 2016; 491: 64-72.
6.Duan, Liangwei; Du, Jiansen; Liu, Xinqi*, Insights into vaccine development for acquired immune deficiency syndrome from crystal structures of human immunodeficiency virus-1 gp41 and equine infectious anemia virus gp45;Protein Science, 2015; 24(10): 1549-1559.
7. Lou, Yunwei#, Song, Miaomiao#, Han, Meijuan, Zhong, Jiateng, Tian, Xueqin, Ren, Yahan; Song, Yaru,Duan, Liangwei; Zhao, Peiqing; Song, Xiangfeng; Zhang, Wen; Chen, Youhai H.; Wang, Hui*, Tumor Necrosis Factor-α–Induced Protein 8-Like 2 Fosters Tumor-Associated Microbiota to Promote the Development of Colorectal Cancer;Cancer Immunology Research, 2022; 10(3), 354-367.
8. Xie, Wei; Li, Dengwen*; Dong, Dan; Li, Yuanyuan; Zhang, You;Duan, Liangwei; Liu, Xinqi; Meng, Wenxiang; Liu, Min; Zhou, Jun*,HIV-1 exposure triggers autophagic degradation of stathmin and hyperstabilization of microtubules to disrupt epithelial cell junctions;Signal Transduction and Targeted Therapy, 2020; 5(1): 79.
9. Zhang, Yun#; Tan, Wenqing#; Zhang, Yang; Mao, Huili; Shi, Shuyou; Duan, Liangwei; Wang, Hui; Yu, Junping*, Ultrasensitive and selective detection of Staphylococcus aureus using a novel IgY-based colorimetric platform;Biosensors and Bioelectronics, 2019; 142: 111570.
10.Chen, Guo#; Han, Zhe#; Feng, Du; Chen, Yanfang; Chen, Linbo; Wu, Hao; Huang, Li; Zhou, Changqian; Cai, Xiangyu; Fu, Changying; Duan, Liangwei; Wang, Xiaohui; Liu, Lei; Liu, Xinqi; Shen, Yuequan; Zhu, Yushan*; Chen, Quan*, A Regulatory Signaling Loop Comprising the PGAM5 Phosphatase and CK2 Controls Receptor-Mediated Mitophagy;Molecular Cell, 2014; 54(3): 362-377.
【知識(shí)產(chǎn)權(quán)（包括專利）】
1.劉新奇;段良偉;一種潛在的高效重組HIV-1 CRF07-BC gp140免疫原的制備方法2017-3-29中國CN201410160156.6（授權(quán)專利）
2.段良偉;王輝;鄭前前;牛玉娜;牛志國;張佳璐;劉夢(mèng)楠;一種重組EBV gHgL免疫原的制備方法及其應(yīng)用2022-6-20中國CN202010026943.7（授權(quán)專利）
【學(xué)術(shù)任職】
《Biocell》editor;《Microbiology Spectrum》和《Scientific Reports》等期刊審稿人。
